{
  "created_at": "Fri Aug 20 1:8:20 +0000 2021",
  "id_str": "1428333436541018121",
  "full_text": "Vaccine makers Pfizer and Moderna are on track to notch billions more in sales than previously expected, as new booster-shot strategies and concerns about the Delta variant push demand, and the companies raise prices in the U.S. and elsewhere https://t.co/Jto6ZwwxZB",
  "display_text_range": [
    0,
    266
  ],
  "entities": {
    "hashtags": [],
    "symbols": [],
    "user_mentions": [],
    "urls": [
      {
        "url": "https://t.co/Jto6ZwwxZB",
        "expanded_url": "https://on.wsj.com/3k6dPMj",
        "display_url": "on.wsj.com/3k6dPMj",
        "indices": [
          243,
          266
        ]
      }
    ]
  },
  "user": {
    "name": "The Wall Street Journal",
    "screen_name": "WSJ",
    "profile_image_url_https": "https://pbs.twimg.com/profile_images/971415515754266624/zCX0q9d5_normal.jpg"
  },
  "retweet_count": 41,
  "favorite_count": 73,
  "possibly_sensitive": false,
  "original_created_at": "Thu Aug 19 12:30:03 +0000 2021",
  "localize": [
    {
      "locale": "ja",
      "full_text": "ワクチンメーカーのPfizer社とModerna社は、これまでの予想を上回る数十億ドルの売上を達成する見込みです。これは、新たなブースターショット戦略とデルタバリアントに関する懸念が需要を押し上げ、米国やその他の地域で価格を引き上げるためです。https://t.co/Jto6ZwwxZB"
    },
    {
      "locale": "zh",
      "full_text": "疫苗制造商辉瑞公司和Moderna公司的销售额将比之前的预期多出数十亿美元，因为新的强化注射策略和对Delta变体的担忧推动了需求，并且这些公司在美国和其他地方提高了价格https://t.co/Jto6ZwwxZB。"
    },
    {
      "locale": "zh-Hant",
      "full_text": "疫苗製造商輝瑞公司和Moderna公司的銷售額將比之前的預期多出數十億美元，因爲新的強化注射策略和對Delta變體的擔憂推動了需求，並且這些公司在美國和其他地方提高了價格https://t.co/Jto6ZwwxZB。"
    }
  ]
}